About Forest

Forest has well-established franchises in multiple therapeutic areas, and we are always exploring new product opportunities that address a range of health conditions. Our principal brands include BYSTOLIC® (nebivolol), DALIRESP® (roflumilast), FETZIMA (levomilnacipran extended-release capsules), LINZESS® (linaclotide), NAMENDA® (memantine HCl), NAMENDA XR® (memantine HCl), SAPHRIS® (asenapine), SAVELLA® (milnacipran HCl), TEFLARO® (ceftaroline fosamil) for injection, TUDORZA® PRESSAIR® (aclidinium bromide inhalation powder), and VIIBRYD® (vilazodone HCl).

Forest identifies, develops, and delivers pharmaceutical products that make a difference in people's lives. We have been extremely successful in meeting our business objectives and expanding our franchises, but we also derive satisfaction in helping to bring relief to people who are suffering. We credit our success to our innovation, integrity, and commitment to developing important products.

A unique approach to product development

To provide innovative and effective medicines, we rely on a strategy that is straightforward and successful:

  • License promising new products from innovative companies worldwide at virtually every stage of development
  • Conduct rigorous scientific investigation and development of drug therapies that make a unique contribution to the field of healthcare and the lives of patients
  • Execute superior marketing and sales initiatives to firmly establish our products in the marketplace

Built on integrity

Forest proudly and actively promotes professional behavior and personal integrity in every aspect of our business operations. We believe that the highest ethical behavior is consistent with our ambition to deliver therapies that will favorably impact the health and well-being of patients.

What's ahead for Forest?

At Forest, we believe in the power of potential—the potential of science, purpose, and people. As a nimble pharmaceutical company, we are dedicated to concentrating our energies and using our experience to bring important treatments to the marketplace.

We are proud of our success and excited by our potential. We anticipate continued, steady growth in our product pipeline, revenues, and workforce. Learn more about Forest by exploring our products, investor relations, and careers.

KEY PHARMACEUTICAL PRODUCTS

BYSTOLIC® (nebivolol)
BYSTOLIC full Prescribing Information

DALIRESP® (roflumilast)
DALIRESP full Prescribing Information

FETZIMA (levomilnacipran extended-release capsules)
FETZIMA full Prescribing Information, including Boxed Warning

LINZESS® (linaclotide)
LINZESS full Prescribing Information, including Boxed Warning

NAMENDA® (memantine HCl)
NAMENDA full Prescribing Information

NAMENDA XR® (memantine HCl)
NAMENDA XR full Prescribing Information

SAPHRIS® (asenapine)
SAPHRIS full Prescribing Information, including Boxed Warning

SAVELLA® (milnacipran HCl)
SAVELLA full Prescribing Information, including Boxed Warning

TEFLARO® (ceftaroline fosamil) for injection
TEFLARO full Prescribing Information

TUDORZA® PRESSAIR® (aclidinium bromide inhalation powder)
TUDORZA PRESSAIR full Prescribing Information

VIIBRYD® (vilazodone HCl)
VIIBRYD full Prescribing Information, including Boxed Warning

 

FOREST AT-A-GLANCE

Chairman of the Board:
Howard Solomon

CEO & President:
Brenton L. Saunders

Corporate Headquarters:
New York, New York

Year Founded:
1954 (incorporated 1956)

Employees (global):
Approx. 5,800

Sales Force:
Approx. 3,500

FY 2013 Revenues:
$3,126 (US$ Mil.)

STOCK EXCHANGE LISTING

New York Stock Exchange (FRX)

WEBSITE

www.frx.com